title: [Growth chamber assay, a novel chemosensitivity test which eliminates normal stromal cells].
abstract: The chemosensitivity test with growth chamber (GC), a semi permeable polymer matrix, was conducted using human tumor xenografts, comparing the results with those of in vivo nude mouse system. Xenografts used were MX-1, St-4, Co-3, and Co-4. Normal stromal cells, SM-74, a cell line derived from human adult skin fibroblast, and Clone-A-31, a cell line from BALB/c nu/nu nude mice were used as the control. Dissociated tumor cell suspension in 200 microliters of Medium 199 was plated into GC (80,000 cells, chamber) and incubated with a various concentration of mitomycin C(MMC), cisplatin (DDP), 5-fluorouracil (5-FU), and adriamycin (ADM) at the various concentrations. After incubation of 1 wk, the activity of hexosaminidase was measured with ELISA assay using p-nitrophenyl-N-acetyl-glucosaminide. The antitumor activity of the agents against human tumor xenografts was dose dependent, and the antitumor spectra obtained by GC assay was essentially identical to in vivo nude mouse system. On the other hand, no evaluable optical density could be obtained with normal stromal cells, SM-74 and Clone-A-31. The optimal cutoff concentration of each drugs to predict the in vivo results was estimated to be 10 micrograms/ml for MMC, 15 micrograms/ml for DDP and 5-FU, and 0.7 microgram/ml for ADM. The predictability of GC assay was 77%, including 89% sensitivity and 70% specificity. Since GC assay could eliminate the normal stromal cells because of the characteristic of chamber surface, this assay was thought to be useful for the clinical chemosensitivity test of human cancers containing a large number of normal stromal cells.
authors.affiliation: Dept. of Surgery, Keio University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Tetsuya
authors.forename: K
authors.initials: K
authors.lastname: Tetsuro
authors.forename: Y
authors.initials: Y
authors.lastname: Hiroshi
authors.forename: T
authors.initials: T
authors.lastname: Touru
authors.forename: F
authors.initials: F
authors.lastname: Toshiharu
authors.forename: K
authors.initials: K
authors.lastname: Suguru
authors.forename: K
authors.initials: K
authors.lastname: Susumu
authors.forename: I
authors.initials: I
authors.lastname: Kyuya
authors.forename: A
authors.initials: A
authors.lastname: Osahiko
authors.forename: Y
authors.initials: Y
authors.lastname: Hirokazu
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D012878:Skin Neoplasms / Q000473:pathology
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil